Transplantation is a successful treatment for end-stage organ failure. Despite improvements in short-term outcome, long-term survival remains suboptimal because of the morbidity and mortality associated with long-term use of immunosuppression. There is, therefore, a pressing need to devise protocols that induce tolerance in order to minimize or completely withdraw immunosuppression in transplant recipients. In this review we will discuss how regulatory T cells (Tregs) came to be recognized as an attractive way to promote transplantation tolerance. We will summarize the preclinical data, supporting the importance of these cells in the induction and maintenance of immune tolerance and that provide the rationale for the isolation and expansion of these cells for cellular therapy. We will also describe the data from the first clinical trials, using Tregs to inhibit graft-versus-host disease (GVHD) after haematopoietic stem cell transplantation and will address both the challenges and opportunities in human Treg cell therapy.
Introduction
Advances in surgical techniques and the introduction of T cell-directed immunosuppressive agents has made solid organ transplantation a well-established treatment for endstage failure of several major organs. Despite improvements in short-term outcome, long-term patient and graft survival remain suboptimal due to the toxic side effects associated with long-term use of these drugs. A major goal of transplantation research is, therefore, to promote 'tolerance' , a state in which the host's immune system can be reprogrammed and then guided to accept a transplant without the need for long-term immunosuppression. In this pursuit, clinically applicable protocols aim to tip the balance in favour of regulation by either the in-vivo expansion of T cells with regulatory activity or the infusion of ex-vivo expanded cells.
The past two decades have seen the discovery of many different types of regulatory T cells, including: CD8 + T cells [1] , CD4 -CD8 -double-negative T cells [2] , CD8 + CD28 - [3] , natural killer (NK) T cells [4] and gd T cells [5] , but these are less well studied compared to CD4 + regulatory T cells (Tregs) . In this review we will focus on the potential for clinical application of CD4 + Tregs, characterized by high and stable expression of surface interleukin (IL)-2 receptor a chain (IL-2Ra, CD25 hi ) and the transcription factor, forkhead box protein 3 (FoxP3) [6] . These CD4
FoxP3
+ cells are thymus-derived, referred to as natural Tregs (nTregs), compared to their counterparts that are generated in the periphery and whose activation requires T cell receptor engagement and cytokines, the induced Tregs (iTregs) [7, 8] .
In comparison to iTregs, studies support the more potent and stable role of nTregs (referred to hereafter as Tregs) in maintaining self-tolerance and preventing autoimmunity [9] . The ability to expand such cells has, therefore, become an attractive prospect in modulating immune responses not only in the context of solid organ transplantation, but also in autoimmunity and prevention of graft-versus-host disease (GVHD). The rationale is based on animal models and clinical studies that have demonstrated clearly that Treg deficiency and/or functional defects might contribute to the pathophysiology of several autoimmune diseases such as type I diabetes, multiple sclerosis, rheumatoid arthritis, as well as organ rejection (reviewed in [10] ).
In the context of organ transplantation, it is of paramount importance to understand the way in which alloreactive CD4
+ T cells see alloantigen in order to better dictate the strategies used for the clinical application of Tregs. The two main pathways of allorecognition include the direct pathway [graft-derived cells are recognized by their surface expression of intact major histocompatibility (MHC) alloantigens], and the indirect pathway [recipient antigenpresenting cells (APC) present donor MHC alloantigens in the context of self-MHC [11] ]. Direct allorecognition is a vigorous reaction due to the high precursor frequency of alloreactive T cells; in this regard it is generally accepted that deletion of a substantial proportion of direct pathway alloreactive T cells will be required to 'tip the balance' from reactivity to regulation [12, 13] . In addition, in order to suppress the surviving alloreactive T cells by regulation one would need sufficient numbers of Tregs in the right place, at the right time, in an environment that favours regulation. Therefore, the specificity of the Tregs chosen for cellular therapy may play an important role (discussed in later sections). The main focus of this review is the clinical application of Tregs in the setting of transplantation and the journey from bench to bedside. We will discuss the challenges that we still face in the laboratory from the isolation to the ex-vivo expansion of these cells for immunotherapy and outline the questions that still remain with regard to the clinical protocols. Moreover, human Tregs are currently less well-characterized and understood compared to mouse Tregs; we will, therefore, review briefly their biology before discussion of their clinical application.
Regulatory T cells (Tregs)

Markers used for isolation
Aside from the expression of CD25 [14] and FoxP3 (outlined above), human Tregs also express CD27 [15] , CD45RA [16] , CD39 [17] , CD122, cytotoxic T lymphocyte antigen-4 (CTLA-4 or CD152) and the glucocorticoid-induced tumour necrosis factor receptor (GITR) family-related gene [18, 19] . However, most of these cell surface markers are not exclusive to Tregs, with some of these markers also expressed by non-regulatory CD4 + T cells, posing a challenge during the isolation process. As an example, data support the key role of FoxP3 in the development, maintenance and function of Tregs with supporting evidence that point mutations in the FoxP3 gene leads to a functional Treg deficit that is evident in patients with IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) [20] .
Despite this, FoxP3 is not a sufficient marker for the isolation of Tregs, as many activated effector T cells also express FoxP3 without having a regulatory phenotype [21] [22, 23] . The search for further surface markers to aid in the unique identification of Tregs has led to studies showing that Tregs also express low levels of CD127, the a-chain of the IL-7 receptor [24] . Accordingly, the constitutive high expression of CD25 but low expression of CD127 has been used to discriminate Tregs from activated effector T cells [25] . However, the combination of CD25 and CD127 is still not sufficient to isolate functionally pure Tregs, bearing in mind that not all the ex vivo-isolated FoxP3 + Tregs are regulatory.
Such studies, therefore, highlight the fact that despite all the efforts to identify Treg markers, the quest continues and we have yet to find markers that define 'pure' Treg populations for the purposes of cellular therapy.
Mechanism of action
Several mechanisms of suppression by Tregs have been proposed. Tregs can suppress the functional ability of both CD4 + and CD8 + T cells directly by preventing their differentiation, activation and proliferation via either cell-cell contact or a contact-independent route, which includes inhibitory cytokines such as IL-10, transforming growth factor (TGF)-b and recently IL-35 [26] [27] [28] . They can also kill effector T cells directly in a perforin-dependent and granzyme-dependent manner or suppress their activation [29, 30] . Furthermore, Tregs have been shown to express galectin-1, with blockade of galectin-1 binding to activated T cells being shown to reduce the Treg inhibitory effect [31] .
Moreover, Tregs may mediate their suppressive function by acting directly on dendritic cells (DCs), attenuating their antigen-presenting and co-stimulatory functions. In support of this, Fassbender et al. [32] showed that the co-culture of murine DCs with Tregs led to an increase in DC cyclic adenosine monophosphate (cAMP), which was responsible for the down-regulation of the co-stimulatory molecules, CD80/CD86. Other mechanisms include the role of cytotoxic T lymphocyte antigen 4 (CTLA-4), a negative co-stimulatory molecule on Tregs, in either up-regulating indoleamine 2, 3-dioxygenase (IDO) expression on DCs which, in turn, down-regulated immune responses [33] , or acting as an effector molecule to inhibit CD28 co-stimulation by the cell-extrinsic depletion of costimulatory ligands [34] .
As evident from the studies outlined, therefore, it becomes clear that the precise mechanism of suppression by Tregs has yet to be fully elucidated.
Preclinical data in support of adoptive Treg cell therapy
The term 'adoptive immunity' was first coined in 1954 by Billingham et al. [35] , who were able to show that passive transfer of primed immune cells can generate immunity in the recipient. Subsequently, numerous animal studies have demonstrated the effectiveness of this adoptive transfer of immunity towards cancer and infectious disease [36, 37] . Moreover, the use of IL-2 permitted, for the first time, the ex-vivo culture and expansion of T cells in humans [38] . In addition, many transplant researchers found that CD4 + T cells were responsible for donor-specific tolerance, and it was the study by Hall et al. [39] which concluded that transplant tolerance was mediated by CD4 +
CD25
+ cells. In this study they showed that in cyclosporin-treated rats with long-term cardiac allograft survival, the adoptive transfer of CD4 +
+ T cells resulted in tolerance. The application of Tregs in the context of organ transplantation is supported further by the seminal work by Sakaguchi et al. [6] , who showed that Tregs from naive mice prevented rejection of allogeneic skin grafts in T celldeficient nude mice given CD25 -T cells. Subsequently, a series of preclinical rodent models of skin and cardiac transplantation demonstrated that Tregs present in the recipient at the time of transplantation are critical in the induction and maintenance of tolerance (reviewed in [40] ). In support of such studies we have also generated Treg lines in vitro, and shown that these Tregs are very effective at inducing survival of MHC-mismatched heart allografts [41] . Furthermore, in a murine skin transplant model following thymectomy and partial T cell depletion, we have demonstrated previously the ability of in-vitro-expanded Tregs in inducing donor-specific transplantation tolerance in this system [42] .
The importance of adoptive Treg therapy in transplantation is supported further in mouse models of bone marrow transplantation, where the transfer of freshly isolated Tregs together with the bone-marrow allograft has been shown to ameliorate GVHD and facilitate engraftment [43] . GVHD was also the first model in which it was shown that the adoptive transfer of ex-vivo-expanded donor Tregs was highly effective in preventing acute or chronic GVHD [44] . Moreover, the adoptive transfer of Tregs has been shown to prevent rejection of pancreatic islet [45] and other organ allografts [46, 47] .
The use of currently available humanized mouse models of GVHD and allotransplantation [48, 49] has reinforced further the importance of Tregs in these settings. These models are based on the reconstitution of immunodeficient mice with human immune cells. More recently we have also shown the efficacy of human Tregs in preventing alloimmune dermal tissue injury in a humanized mouse model of skin transplantation [50] . Furthermore, Nadig et al. [51] developed a human vessel graft model to study the in-vivo function of Tregs. Their results showed convincingly that grafts from mice reconstituted with peripheral mononuclear cells (PBMCs) alone exhibited extensive vasculopathy, whereas the co-transfer of Tregs prevented this process.
Such adoptive transfer experiments in rodents, therefore, support the notion that tolerance requires 'tipping the balance' between reactivity and regulation. Despite such data generated in preclinical animal models, showing successfully that Tregs can induce and maintain transplantation tolerance, we currently face many challenges in the laboratory that have hindered the widespread application of Treg cell therapy in the transplant setting. In addition, a number of different strategies have been proposed for the isolation and expansion of Tregs for cellular therapy. However, there is no consensus on the optimal process, and many such processes have their limitations (discussed below).
Clinical application of human Tregs: challenges with large-scale manufacture
Isolation and expansion
One of the obstacles in the implementation of clinical protocols using Tregs is their low frequency, 1-3% of total peripheral blood CD4
+ T cells, and data (from animal models) which suggest that, for these cells to suppress immune responses, high doses of Tregs in relation to effectors is required [52, 53] . This means that for cellular therapy, it will almost certainly be necessary to use a polyclonal stimulus to expand Tregs in vitro. In this regard, the large-scale ex-vivo expansion of human Tregs by stimulation with anti-CD3 and anti-CD28 monoclonal antibody-coated beads and high-dose IL-2 has been demonstrated successfully [54] . However, effectors have the potential to proliferate vigorously under such conditions, so that even a trace of effectors in the starting population can be expanded in high numbers. The injection of such cells would, therefore, be detrimental to the patient and may lead to rejection. Thus, it is essential to either initiate the expansion culture with highly purified Tregs (a challenge in view of the absence of a Treg-specific cell surface marker) or create culture conditions that favour Treg cell growth.
Two different combinations of markers appear to be promising for Treg isolation. The first seeks to isolate CD4 +
CD25
hi Tregs, but with the addition of an antibody to select for CD45RA + cells and so eliminate antigenexperienced or memory T cells [16] . The second combination also uses the CD4 +
hi phenotype, but includes CD127 expression. The rationale for using CD127 as a marker for Treg isolation (as explained in earlier sections) is on the basis that in human Tregs there is a reciprocal expression of CD127 and FoxP3, and thus CD127 provides a sortable surrogate marker for FoxP3 + Tregs [24] . Moreover, the so-called 'naive' Treg population based on the co-expression of CD4 and CD45RA yield Tregs with a greater suppressive capacity than total CD25 hi cells [55] . The reason for this became clear when Miyara et al. [22] noted the subpopulations of human FoxP3
+ T cells and discovered that the CD25
hi cells contain many Th17 precursors. Furthermore, after 3 weeks of in-vitro expansion the CD45RA + -expanded Tregs remained demethylated (compared to the CD127 -Tregs that became methylated) at the Treg-specific demethylation region (TSDR), which is a conserved region upstream of exon 1 within the FoxP3 locus [completely demethylated in natural Tregs but methylated fully in induced Tregs and effector T cells (Teff)] [55, 56] . Such studies, therefore, support the isolation of Tregs based on CD45RA
+ expression, bearing in mind that they are the most stable population for expansion and have the greatest expansion potential [16] . Despite such studies, one drawback is that the number of naive Tregs declines in the peripheral blood with age [57] , and hence isolation based on CD127 expression may still be a practical approach. Moreover, two elegant studies by Kathryn Wood's group [51, 58] support the in-vivo superiority of the CD4
Tregs at regulating alloreactivity compared to Tregs isolated based on the expression of CD4 and CD25 alone. Such studies have important implications for the design of future clinical studies.
The search for further surface markers to aid the isolation of purer or more potent Treg populations led to studies investigating markers such as CD121a/CD121b, TGF-b/ latency associated peptide (LAP) [59] and CD39 [60] . However, all these proteins are expressed only on activated Tregs and would be of use only to re-isolate Tregs after expansion. This may not be feasible, in view of the costs of re-isolating billions of Tregs on a per-patient basis. Other studies complicate the story even further. Ito et al. [61] showed that FoxP3 + Tregs could be grouped into two subsets based on the expression of the inducible T cell co-stimulator (ICOS). 
+ Tregs qualify as the best candidate for in-vitro expansion. Such studies, therefore, paint a complicated picture that when choosing the Treg marker for cell isolation we should also bear in mind other factors other than simply purity, i.e. isolating potent cells with a mechanism of action to suppress the immune response of interest and cells with the desired expansion profiles.
Despite this, however, what limits choice when devising a clinically applicable protocol is that isolation techniques need to be good manufacturing practice (GMP)-compliant, and GMP purification reagents for all the various markers outlined above are not yet available.
The clinical Treg selection protocols used to date in the United Kingdom have used a combination of depletion and positive selection steps, with the isolation tools involving mainly the automated CliniMACS plus system (Miltenyi Biotec, Bisley, UK). This enables GMP-compliant cell selection by magnetic bead activated cell sorting [63] . More specifically, for the production of CD4
hi Tregs the GMP-grade antibodies available enable the depletion of CD19/CD8-expressing immune cells followed by a positive selection of CD25-expressing T cells [64] . The major drawback with such techniques is that this process does not guarantee the selection of CD25
hi cells compared to the fluorescence activated cell sorter (FACS) sorter, which allows the important distinction to be made between the CD4 +
hi and CD25 int cells. In addition, the process does not allow the selection of Tregs based on multiple parameters and the~60% purity of the isolated cells [65] is not comparable with the >95% purity achieved using the FACS sorter [56] .
In addition to the automated CliniMACS plus system (Miltenyi Biotec), there are two other commercially available methods for GMP-grade T cell isolation and expansion. Life Technologies Ltd (Paisley, UK) produces the DynaMag TM CTS TM system, which is a magnetic device used in combination with the Dynabeads® CTS™ and Dynabeads® ClinExVivo™ to positively isolate bead bound cells or deplete unwanted cell types. Dynabeads® CD3/CD28 CTS™ are used to positively isolate T cells; these beads are also able to activate the bound T cells and when cultured in the presence of IL-2 result in a 100-1000-fold expansion of the isolated T cells. The T cells are purified by labelling cells with mouse immunoglobulin (Ig)G1 antibodies and using the Dynabeads® IgG1 Binder CTS™ for positive isolation, negative isolation or cell depletion.
Stage Cell Therapeutics (Göttingen, Germany) is a cell therapy company that manufactures Streptamer® reagents for isolation of defined lymphocytes. In view of isolating purer Treg populations, their system involves three positive selection steps by magnetically tagged Fab-Streptamers.
Following each labelling and positive selection step, the tagged cells are liberated completely from the magnetically tagged Fab-Streptamers by incubation with a competing Streptactin ligand D-biotin that causes disruption of the Fab-multimer complex, dissociation of the Fab-Streptamer label from the target cell surface and complete removal upon washing. The first positive isolation step involves anti-CD4-Fab-Streptamer labelling, followed by anti-CD25-Fab-Streptamer labelling, and finally anti-CD45RA-Fab-Streptamer labelling is used to isolate a triple-positive Treg cell preparation that is CD4
Interestingly, however, the study by Marek et al. [66] showed that regardless of the initial phenotypic markers used for isolation (i.e. CD25 hi CD127 low , CD45RA + , CD45 RA -) during the expansion process, Tregs were transforming into effector/memory-like cells which produced inflammatory cytokines. They proposed that independent of the phenotypic markers used for Treg isolation, the only variable to help maintain the Treg phenotype and function was limiting the expansion time to 2 weeks. Based on such studies, therefore, it is of particular importance to ensure that the stability of the Tregs is maintained during the expansion process.
Basu et al. [67] described a method for the expansion of Tregs in the presence of the immunosuppressant, rapamycin (sirolimus). They showed that rapamycin inhibits preferentially the proliferation and function of CD25 + conventional effector T cells and thus permits the expansion of Tregs even from a mixed starting population [67, 68] .
Furthermore, and in support of such a study, Tresoldi et al. [69] showed that only the expansion cultures in the absence of rapamycin are contaminated by the CD4
+ T helper type 17 (Th17) precursor cells. Despite this promise, adding rapamycin to Treg cultures has its own disadvantages in view of diminishing overall Treg expansion [70] . The addition of rapamycin may, therefore, necessitate extended expansion times in order to achieve the therapeutic numbers -a problem, bearing in mind studies showing loss of FoxP3 expression in human Tregs upon repetitive stimulation (mentioned earlier [55] ). It is also important to consider that target doses of expanded Tregs may not always be reached, as reported in a clinical trial by Brunstein et al. [71] , even when using protocols without the addition of rapamycin. Such trials used anti-CD3/CD28 beads for stimulation and expansion of the Treg lines, the only GMP reagents available (with a safety record in humans). However, stimulation with cell-based artificial APCs (aAPCs), expressing the co-stimulatory molecule CD86 and an Fc receptor (FcR) for loading of anti-CD3 monoclonal antibody (mAb), has also been used to expand Tregs [72] with approximately fourfold superiority over the use of anti-CD3/CD28 beads.
These studies, therefore, highlight the many obstacles that we still need to overcome to refine further the current protocols for the isolation and expansion of Tregs to ensure safe and efficacious application in the clinical setting.
Despite these hurdles in the laboratory, there is still much debate over the specifics of the clinical protocol (outlined below).
Clinical protocol
Immunosuppression and timing of Tregs
Most transplant recipients are treated with a combination of immunosuppressive drugs and biological agents to control rejection and/or GVHD responses. The combination of drugs used varies depending on the type of organ being transplanted as well as the protocols used by individual transplant centres. For example, some countries use induction therapy with monoclonal or polyclonal antibody preparation such as alemtuzumab or anti-thymocyte globulin (ATG) at the time of transplantation. This treatment markedly depletes most of the leucocyte populations in the peripheral blood. Interestingly, leucocyte depletion has the potential to tip the balance in favour of immune regulation by creating a situation whereby regulatory immune cells outnumber the effector cells. However, whether or not induction therapy is used, when devising clinical protocols to incorporate Tregs it is crucial to take into account the influence of the various immunosuppressants on the Tregs in vivo.
Taking the example of ATG, the data indicate that in both adults and children ATG causes a rapid decrease in naive CD4 and CD8 T cells which persist usually for at least 2 months [73] . In addition, it has been shown that treatment with ATG is associated with the expansion of FoxP3 + T cells in vivo and suggests a shift in Treg to a Teff ratio. Despite this, CD4
+ and CD8 + memory cells are resistant to depletion by ATG and these cell subsets expand over the initial 6 months post-transplantation [73] . The fact that memory cells survive deletion may explain why patients do not suffer opportunistic infections post-ATG therapy. However, these cells can contribute to early graft injury and loss and, importantly, these cells are more resistant to suppression by Tregs than naive T cells [74] . However, to limit memory T cell expansion (post-induction therapy), transplant recipients are maintained on other immunosuppressive drugs, most commonly a calcineurin inhibitor (CNI) such as tacrolimus or cyclosporin A, and an anti-proliferative agent such as mycophenolate mofetil. It has been proposed that both types of drug inhibit the generation and function of Tregs. Despite this, in animal models in the context of autoimmunity it has been shown that for Tregs to exert their suppressive function tissue inflammation needs to be controlled [75] . It seems that for Tregs to expand in vivo and exert their suppressive function they require a tolerogenic milieu. In support of this, a recent study analysing the dynamics of the alloimmune response in vivo demonstrated a rapid invasion of effector cells in the grafts followed by the delayed arrival of Tregs that were ineffective at controlling tissue damage [76] . In contrast, when the recipient mice were treated with anti-CD40L mAb and rapamycin, effector T cell infiltration was delayed and more than 30% of the graft infiltrating T cells were Tregs. Of note, there is good evidence in the literature indicating that rapamycin is superior to tacrolimus for the thymic export and survival of Tregs [77, 78] . In contrast to CNIs, rapamycin appears to be tolerance-permissive by selectively inducing apoptosis or necrosis of alloreactive effector cells while promoting Treg induction [79] , expansion [78] and function [80] . This may suggest that rapamycin is the ideal candidate for short-term therapy post-depletion in humans. However, rapamycin monotherapy post-depletion is associated with a high risk of acute rejection [81] , and it is not yet clear whether the concomitant therapy with Tregs would be sufficient to prevent this or whether further immunosuppression will be required in the short term.
The use of combinations of immunosuppressive agents in the clinical setting highlight the challenge associated with designing protocols that include the infusion of Tregs. Thus, the competing actions of each immunosuppressive drug may have to be considered together with the key question of the timing of cell injection.
Most of the preclinical Treg therapy studies published thus far administered Tregs prior to or at the time of transplantation, in contrast to studies of autoimmune disease where it has been shown that Treg therapy after disease initiation can effectively reverse the disease course [82] . The intensity of the anti-allograft response and the fragility of the transplanted organ may explain the lack of efficacy when Treg infusion is delayed. However, if T cell-depleting reagents such as ATG are used as induction therapy, it may be possible to delay Treg infusion until lymphocyte numbers start to recover 2 months or more after transplantation. This might tip the balance between Tregs and Teff cells and help to promote a tolerant state.
Location of Treg function and site of Treg injection
An additional consideration regarding Treg therapy is the site of action of Tregs and, consequently, the desired homing properties of injected cells. In the transplant setting, Treg lymph node homing and their ability to traffic to grafts are both required for their protection against graft rejection [83] . Interestingly, in a mouse islet transplant model, therapeutic Tregs function initially at the graft site (preventing the exit of donor-derived DCs) and then traffic to the draining lymph node and continue to exert their suppressive function there [84] . In so doing, they prevent the exit and migration of donor-derived DCs to the lymph nodes, thereby reducing alloimmune priming. The translation of such a study to the clinic may mean that to ensure that Tregs exert their suppressive function we need to either inject the cells at the graft site or ensure that the cells reach the graft/ lymph node due either to their alloantigen specificity or homing receptor expression. Bearing in mind the serious complications associated with injection of the cells at the graft site, i.e. the risk of bleeding if cells are injected via the portal vein (in the case of liver transplantation), the favoured option is infusion via a peripheral vein.
Studies have shown antigen-specific Tregs to be more potent than polyclonally activated Treg cells [85] [86] [87] . Moreover, Tregs with direct specificity are very potent in preventing acute rejection early after transplantation, while Tregs with indirect specificity seem to be crucial to prevent chronic rejection [42, 46] . In addition, using antigen-specific Tregs would have additional advantages; first, their action would be limited to the site of alloantigen source and immune activation [88, 89] ; and secondly, this may avoid the undesirable pan-suppression, mediated by polyclonal cells, resulting in an increased risk of infections and cancers. However, although the expansion of direct pathway allospecific human Tregs has been achieved [90, 91] , expansion of indirect pathway Tregs has proved more difficult, posing further challenges [92, 93] . It is important to note, however, that despite the evidence supporting the importance of antigenspecific Tregs in preventing solid organ rejection, in GVHD the transfer of Tregs enriched for alloantigen specificity showed only moderately improved efficacy when compared to the polyclonal Treg cell population [94] . Although such studies emphasize the lack of antigen-specific requirement for the transferred Tregs, interestingly, a recent study discussed the importance of homing receptor expression in this transplant setting.
Ukena et al. [95] showed that tolerant patients without GVHD after haematopoietic stem cell (HSC) transplantation expressed significantly higher levels of the chemokine receptors transplantation. This may suggest that homing of Tregs to secondary lymphoid tissue and sites of inflammation may play an important role in the control of GVHD, despite some studies suggesting that GVHD is a systemic disease and the concentration of Tregs at a localized site is not required.
These types of study, therefore, support the notion that therapeutic strategies using Tregs have to take into account the fact that these cells not only need potent suppressive function, but also need appropriate tissue trafficking to enable contact with their target cells. Therefore, if the Tregs are to be injected via a peripheral vein then it is important that they express the molecules such as CD62L and CCR7 that are crucial for their migration to the lymph nodes and other chemokine receptors, e.g. CXCR3 for liver homing [96] . Moreover, Tregs vary in their expression of trafficking and homing receptors according to their individual histories and state of activation. They have been shown to variously express CCR2, CCR4, CCR7, CCR8, CCR9, CXCR1 and CXCR4 (reviewed in [97] ). In addition, it is now known that within the pool of FoxP3-expressing cells functionally diverse Treg subsets can be identified on the basis of chemokine receptor expression [98] . In view of the impor-tance of Treg expression of chemokine receptor and trafficking on their in-vivo suppression function, efforts have been made at understanding the influence of culture conditions on the expression pattern of these receptors on Tregs. In this regard, we and others have shown the expression of guthoming receptors, a4b7, on Tregs cultured in the presence of all-trans retinoic acid (ATRA) (Scotta et al., mauscript submitted). This may have important implications in the use of Treg cell therapy in the context of inflammatory bowel disease. However, ensuring that Tregs express the relevant receptors and maintain their expression during the expansion process is challenging, as indicated by a recent study showing changes in the chemokine receptor expression of Tregs in vitro [99] . In this study they showed that ex-vivocultured Tregs retained the expression of CCR7, but down-regulated CCR5 dramatically compared with freshly isolated Tregs.
Dose of Tregs and number of injections
Aside from the timing of injection and the site of injection, what is of paramount importance is to decide the dose of Tregs that is needed (recently reviewed in [100] ).
The trials to date (outlined below) of Treg therapy in the context of bone marrow transplantation will inform us of the doses that are safe and tolerated in patients. However, the first trials of Treg therapy in solid organ transplantation will need to start with a dose escalation study to assess the safety and tolerability of Tregs at various doses (minimum determined by the trials to date and the maximum number determined by the maximum number of Tregs reached during the in-vitro expansion process). In addition, whether polyclonal Tregs or antigen-specific Tregs are used will influence the dose. Of note, studies using antigen-specific Tregs showed that lower numbers were able to achieve the same functional efficacy as larger numbers of polyclonal Tregs [86, 87] . Finally, whether a single injection or multiple injections are required is a matter of debate and may be determined in a Phase II efficacy study, where patient outcomes should also be measured and an in-depth patient monitoring planned.
The use of molecular diagnostic tools can help to assess the increased expression of biomarkers of operational tolerance in patients receiving cellular therapy and whether these can be used as surrogate end-points of efficacy [101] [102] [103] . The same approach can be used to define whether or not the patients have decreased expression of biomarkers of acute rejection [104, 105] . Furthermore, phenotypic analysis of patient PBMCs, using flow cytometric analysis, can determine whether or not the number of Tregs has increased or the composition of the T cell compartment has changed as a result of the intervention [106] . Using the same analysis, the cytokine profile of the cells that have been phenotyped can be analysed to establish their plasticity. Finally, lymphocyte compartments can be monitored after specific interventions, as has been shown useful when associating expansion of lymphocyte subsets, in this case naive B cells, in peripheral blood of patients in whom better outcomes were noted [107] .
First results of clinical trials
In spite of the potential concerns and controversies outlined with regard to Treg isolation and expansion protocols and the optimal clinical protocol, clinical trials are under way to test the therapeutic potential of Tregs.
Beneficial effects of Treg infusions on allograft survival were first reported in bone marrow transplantation models in which donor Tregs reduced the incidence of GVHD. The first human trial using Treg cell therapy by Trzonkowski et al. [108] involved two patients. The first patient had chronic GVHD 2 years post-bone marrow transplantation. After receiving 0·1 ¥ 10 6 /kg FACS purified ex-vivo-expanded Tregs from the donor, the symptoms subsided and the patient was withdrawn successfully from immunosuppression without evidence of recurrence. The second patient had acute GVHD at 1 month post-transplantation, which was treated with several infusions of expanded donor Tregs. Despite initial and transitory improvement, the disease progressed and resulted ultimately in the patient's death. This was the first report to show that adoptive transfer of Tregs is well tolerated and thus was a major breakthrough.
Results of a larger Phase I/II study were reported in which a total of 23 patients receiving umbilical cord blood (UCB) stem cell transplants were enrolled into a Treg escalation trial [71] . CD4 +
CD25
hi Tregs were isolated from a thirdparty UCB graft and expanded by anti-CD3/CD28-coated beads and recombinant IL-2 over a period of 18 days. Patients received expanded Tregs at doses ranging from 1 ¥ 10 5 to 30 ¥ 10 5 /kg. Of note, the targeted Treg dose was achieved only in 74% of cases. Compared with the 108 historical controls, there was a reduced incidence of grades II-IV acute GVHD (from 61 to 43%; P = 0·05), although the overall incidence of GVHD was not significantly different.
In a third trial (Phase I/II), conducted by Di Ianni et al. /kg Tregs is safe. Moreover, patients receiving Tregs demonstrated accelerated immune reconstitution, reduced cytomegalovirus (CMV) reactivation and a lower incidence of tumour relapse and GVHD when compared to historical controls. However, it is also important to note the disappointing patient survival, with only 13 of the 26 patients surviving, but this may have been because of pre-existing fungal infections and the harsh conditioning regimens that were used.
With the results from stem cell-treated patients showing that Treg therapy is well tolerated, it is now time to initiate trials in solid organ transplantation. In this regard, the ONE Study, a multicentre Phase I/II study funded by the European Union FP7 programme, will investigate the safety of infusing ex-vivo-expanded Treg cells (among other regulatory cells) into kidney transplant recipients. Moreover, clinical trials to test the safety and tolerability of polyclonally expanded or donor alloantigen-specific Treg cell therapy in combination with depletion of alloreactive T cells and short-term immunosuppression in liver transplant patients are currently being planned.
Conclusion
The first results of clinical trials applying Tregs in stem cell transplantation are very encouraging, and provide a basis for future trials in solid organ transplantation. Such trials should involve a small number of patients, aiming at evaluating the safety of increasing doses of Tregs. In addition, the clinical protocol for such trials should be based on a 'Treg-supportive' immunosuppressive regimen, not only to protect against rejection, but also to create the tolerogenic milieu to maximize the potential efficacy of the exogenously administered Tregs. Recent progress in understanding Treg biology and the development of experimental mouse models has highlighted how heterogeneous and plastic murine as well as human Tregs can be. This supports the importance of a careful design of purification and expansion protocols for generating Tregs for clinical application with release criteria set with the most current understanding of Treg biology. Moreover, it is of paramount importance to ensure a comprehensive patient immune monitoring plan and the use of biomarkers that can predict the successful induction of immune tolerance, which would allow for the safe minimization or even withdrawal of immunosuppression.
